Targeted radiation therapy for relapsed neuroblastoma
Part of Cancer clinical trials.
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have neuroblastoma that can be seen on a special scan called MIBG (a scan that shows where the tumor is).
- You must be at least 1 year old.
- You need to be feeling well enough to do daily activities (score of 50% or higher on a standard scale).
- Your organs (like kidneys, liver, and bone marrow) must be working well enough.
- You cannot have had certain cancer treatments (like specific antibodies, radiation therapy, or stem cell transplants) recently, and you must not have serious infections or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two special types of imaging scans that look for neuroblastoma tumors. The imaging uses safe radioactive tracers to help doctors better see the cancer and plan treatment.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
This trial gives a radioactive drug (131I-MIBG) that targets and kills certain nerve tumor cells. It is for people whose neuroblastoma or related tumors have not responded to standard treatments or have come back.
This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.
This trial uses a special radioactive medicine (131I-MIBG) to target and kill cancer cells in people with neuroblastoma or pheochromocytoma that has not responded to other treatments. It may help shrink tumors or slow the disease, and you'll receive a stem cell transplant afterward to help your body recover.
Hear when a new Neuroblastoma (NB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.